Skip to main content
. Author manuscript; available in PMC: 2016 Oct 23.
Published in final edited form as: Cochrane Database Syst Rev. 2015 Oct 23;10:CD006537. doi: 10.1002/14651858.CD006537.pub3
Outcomes at two years Illustrative comparative risks* (95% CI) Relative effect (95% CI) No of participants (eyes, studies) Quality of the evidence (GRADE)
Assumed risk Corresponding risk
Control Photocoagulation
Development of CNV 83 per 1000 89 per 1000 (67 to 117) OR 1.07 (0.79 to 1.46) 2159 (3580 eyes, 11 studies) ⊕⊕⊕⊕
high1
Low risk population (people with bilateral drusen)
50 per 1000 54 per 1000 (40 to 73)
High risk population (people with CNV in the fellow eye)
250 per 1000 268 per 1000 (199 to 365)
Development of geographic atrophy 66 per 1000 84 per 1000 (26 to 241) OR 1.3 (0.38 to 4.51) 148 (148 eyes, 2 studies) ⊕⊕○○
low2
Visual loss of 2–3+ lines of visual acuity 150 per 1000 149 per 1000 (122 to 183) OR 0.99 (0.81 to 1.22) 2002 (3486 eyes, 9 studies) ⊕⊕⊕○
moderate3
Loss of ≥ 0.3 log units of contrast sensitivity 119 per 1000 100 per 1000 (26 to 309) OR 0.82 (0.20 to 3.31) 82 (82 eyes, 1 study) ⊕⊕○○
low2
Reading speed in words/minute The mean reading speed in words/minute in the control groups was100 words/minute The mean reading speed in words/minute in the intervention groups was 12.5 lower (7.2 lower to 32.2 higher) - 44 (44 eyes, 1 study) ⊕⊕○○
low2
Drusen reduction 107 per 1000 522 per 1000 (428 to 614) OR 9.16 (6.28 to 13.4) 570 (944 eyes, 3 studies) ⊕⊕⊕⊕
high4,5
*

The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; CNV: choroidal neovascularisation; OR: odds ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1

Allocation sequence generation and allocation concealment and masking of visual acuity outcome assessors was achieved in half or less of them; however, the larger studies in this meta-analysis were good quality. Other quality items were not a problem for the primary outcome (no downgrade).

2

Small study yielding wide 95% confidence intervals (−2 for imprecision).

3

Visual acuity examiners were masked in less than half of studies (−1 for risk of bias).

4

The three studies included in this analysis had low risk of bias (no downgrade).

5

Estimates were heterogeneous but they both suggest a strong effect (no downgrade).